- 12-06-2024Background: Androgen Receptor (AR) signaling inhibitors, including enzalutamide, are treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), but…
- 19-05-2024Test
- 19-05-2024Test
- 19-11-2023Background Patients with non-functioning pituitary macroadenoma (NFMA) currently have no established medical treatment options. Somatostatin analogues may decrease tumour size,…
- 18-11-2023The androgen receptor (AR) signaling is the most prominent signaling pathway driving tumorigenesis in prostate cancer. As a result, androgen-deprivation…
- 16-11-2023Introduction: Romosozumab, a monoclonal anti-sclerostin antibody, is an osteoporosis drug available in the Netherlands since 2021 indicated for patients with…
- 16-11-2023Introduction: Romosozumab, a monoclonal anti-sclerostin antibody, is an osteoporosis drug available in the Netherlands since 2021 indicated for patients with…
- 16-11-2023Background: Chronic nonbacterial osteomyelitis (CNO) is a rare disease spectrum, which lacks biomarkers for disease activity. Sodium fluoride positron emission…
- 16-11-2023Background: Chronic nonbacterial osteomyelitis (CNO) is a rare disease spectrum, which lacks biomarkers for disease activity. Sodium fluoride positron emission…
- 15-11-2023It is well established that stress and the attendant rise in glucocorticoids (GCs) results in immune suppression. However, recent evidence…
